<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="2">35590317</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2474</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC musculoskeletal disorders</Title>
          <ISOAbbreviation>BMC Musculoskelet Disord</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Prevalence of post-COVID-19 in patients with fibromyalgia: a comparative study with other inflammatory and autoimmune rheumatic diseases.</ArticleTitle>
        <Pagination>
          <StartPage>471</StartPage>
          <MedlinePgn>471</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">471</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12891-022-05436-0</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the prevalence and characteristics of post-COVID-19 (PC) in fibromyalgia (FM) patients.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective, multi-centric, observational study, comparing a group of FM patients (FM group) with another group of patients with other rheumatic diseases (RD group). COVID-19 diagnosis was established by positive polymerase chain reaction or antigen during acute infection or by positive antibodies thereafter. We considered PC diagnosis when symptoms remain after COVID-19. We collected the principal characteristics of COVID-19, the severity of fatigue, waking unrefreshed and cognitive impairment, and persistent symptoms. The American College of Rheumatology (ACR) criteria and the Combined Index of Severity in Fibromyalgia (ICAF) were collected in the FM group.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">RD group (n = 56) had more pneumonia (p = 0.001) and hospital admissions (p = 0.002), but the FM group (n = 78) had a higher number of symptoms (p = 0.002). The percentage of patients with PC was similar between groups (FM group 79.5%; RD group 66.1%, p = 0.081). FM group had more PC symptoms (p = 0.001), more impairment after COVID-19 (p = 0.002) and higher severity of fatigue, waking unrefreshed and cognitive impairment (p &lt;  0.0001). Only loss of smell was more frequent in the FM group (p = 0.005). The FM group with PC (n = 29) showed more severity of the Combined Index of Severity in Fibromyalgia (ICAF) total score and physical factor after COVID-19, while emotional, coping factors and the ACR criteria did not change.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The prevalence of PC in FM patients is similar to RD patients. In FM patients, the presence of PC does not appear to impact the severity of FM.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rivera</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-8147-5881</Identifier>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Francisco Silvela 40, 28028, Madrid, Spain. javierrivera@ser.es.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>GEFISER, Sociedad Española de Reumatología, Barcelona, Spain. javierrivera@ser.es.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rodríguez</LastName>
            <ForeName>Tamara</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>GEFISER, Sociedad Española de Reumatología, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital Clínic de Barcelona, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pallarés</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Francisco Silvela 40, 28028, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castrejón</LastName>
            <ForeName>Isabel</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Francisco Silvela 40, 28028, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>González</LastName>
            <ForeName>Teresa</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Francisco Silvela 40, 28028, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vallejo-Slocker</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Psychology, National Distance Education University (UNED), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Molina-Collada</LastName>
            <ForeName>Juan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Francisco Silvela 40, 28028, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Montero</LastName>
            <ForeName>Fernando</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Francisco Silvela 40, 28028, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arias</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital Clínic de Barcelona, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vallejo</LastName>
            <ForeName>Miguel A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Psychology, National Distance Education University (UNED), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alvaro-Gracia</LastName>
            <ForeName>Jose M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Francisco Silvela 40, 28028, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Collado</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>GEFISER, Sociedad Española de Reumatología, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital Clínic de Barcelona, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Musculoskelet Disord</MedlineTA>
        <NlmUniqueID>100968565</NlmUniqueID>
        <ISSNLinking>1471-2474</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005356" MajorTopicYN="Y">Fibromyalgia</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Fibromyalgia</Keyword>
        <Keyword MajorTopicYN="N">Long COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Post COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Rheumatic diseases</Keyword>
      </KeywordList>
      <CoiStatement>All authors declare not to have any financial conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>23</Hour>
          <Minute>47</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35590317</ArticleId>
        <ArticleId IdType="pmc">PMC9117853</ArticleId>
        <ArticleId IdType="doi">10.1186/s12891-022-05436-0</ArticleId>
        <ArticleId IdType="pii">10.1186/s12891-022-05436-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Callard F, Perego E. How and why patients made long Covid. Soc Sci Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId>
            <ArticleId IdType="pmc">PMC7539940</ArticleId>
            <ArticleId IdType="pubmed">33199035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–605. doi: 10.1001/jama.2020.12603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId>
            <ArticleId IdType="pmc">PMC7349096</ArticleId>
            <ArticleId IdType="pubmed">32644129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al.  Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. doi: 10.1038/s41591-021-01283-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId>
            <ArticleId IdType="pmc">PMC8893149</ArticleId>
            <ArticleId IdType="pubmed">33753937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13(1):1957.</Citation>
        </Reference>
        <Reference>
          <Citation>Dennis A, Wamil M, Kapur S, Alberts J, Badley AD, Decker GA, et al. Multi-organ impairment in low-risk individuals with long COVID [internet]. Health Policy. 2020; Oct [cited 2021 Aug 21]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.10.14.20212555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2020.10.14.20212555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein H, Asseo K, Karni N, Benjamini Y, Nir-Paz R, Muszkat M, et al.  Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients. Clin Microbiol Infect. 2021;27(5):769–774. doi: 10.1016/j.cmi.2021.02.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmi.2021.02.008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.</Citation>
        </Reference>
        <Reference>
          <Citation>The European Network on ME/CFS (EUROMENE) Rasa S, Nora-Krukle Z, Henning N, Eliassen E, Shikova E, et al.  Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) J Transl Med. 2018;16(1):268. doi: 10.1186/s12967-018-1644-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-018-1644-y</ArticleId>
            <ArticleId IdType="pmc">PMC6167797</ArticleId>
            <ArticleId IdType="pubmed">30285773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baio P, Brucato A, Buskila D, Gershwin ME, Giacomazzi D, Lopez LR, et al.  Autoimmune diseases and infections: controversial issues. Clin Exp Rheumatol. 2008;26(Supp. 48):74–80.</Citation>
        </Reference>
        <Reference>
          <Citation>Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11(1):37. doi: 10.1186/1471-2377-11-37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2377-11-37</ArticleId>
            <ArticleId IdType="pmc">PMC3071317</ArticleId>
            <ArticleId IdType="pubmed">21435231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al.  Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575. doi: 10.1136/bmj.38933.585764.AE.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId>
            <ArticleId IdType="pmc">PMC1569956</ArticleId>
            <ArticleId IdType="pubmed">16950834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Katz RS, Mease P, et al.  The American College of Rheumatology Preliminary Diagnostic Criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62(5):600–610. doi: 10.1002/acr.20140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.20140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rampakakis E, Ste-Marie PA, Sampalis JS, Karellis A, Shir Y, Fitzcharles M-A. Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open. 2015;1(e000146):1.</Citation>
        </Reference>
        <Reference>
          <Citation>Vallejo MA, Rivera J, Esteve-Vives J, Icaf G. Development of a self-reporting tool to obtain a combined index of severity of fibromyalgia (ICAF*) Health Qual Life Outcomes. 2010;8(1):2. doi: 10.1186/1477-7525-8-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1477-7525-8-2</ArticleId>
            <ArticleId IdType="pmc">PMC2822746</ArticleId>
            <ArticleId IdType="pubmed">20055985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallejo MA, Rivera J, Esteve-Vives J, Rejas J, Group ICAF  A confirmatory study of the combined index of severity of fibromyalgia (ICAF*): factorial structure, reliability and sensitivity to change. Health Qual Life Outcomes. 2011;9(1):39. doi: 10.1186/1477-7525-9-39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1477-7525-9-39</ArticleId>
            <ArticleId IdType="pmc">PMC3127741</ArticleId>
            <ArticleId IdType="pubmed">21649886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Häuser W, Katz RS, et al.  Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol. 2011;38(6):1113–1122. doi: 10.3899/jrheum.100594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.100594</ArticleId>
            <ArticleId IdType="pubmed">21285161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718–724. doi: 10.1126/science.abc6027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abc6027</ArticleId>
            <ArticleId IdType="pmc">PMC7402632</ArticleId>
            <ArticleId IdType="pubmed">32661059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dias De Melo G, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F, et al. COVID-19-associated olfactory dysfunction reveals SARS-CoV-2 neuroinvasion and persistence in the olfactory system [internet]. Neuroscience. 2020 Nov [cited 2021 Aug 26]. Available from. 10.1101/2020.11.18.388819.</Citation>
        </Reference>
        <Reference>
          <Citation>Ramos-Casals M, Brito-Zerón P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol [Internet]. 2021; Apr 26 [cited 2021 May 4]; Available from: http://www.nature.com/articles/s41584-021-00608-z.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al.  1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398(10302):747–758. doi: 10.1016/S0140-6736(21)01755-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId>
            <ArticleId IdType="pmc">PMC8389999</ArticleId>
            <ArticleId IdType="pubmed">34454673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, et al.  Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;19:n1098. doi: 10.1136/bmj.n1098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eiros R, Barreiro-Perez M, Martin-Garcia A, Almeida J, Villacorta E, Perez-Pons A, et al. Pericarditis and myocarditis long after SARS-CoV-2 infection: a cross-sectional descriptive study in health-care workers [internet]. Cardiovascular Medicine. 2020 Jul [cited 2021 Aug 29]. Available from:. 10.1101/2020.07.12.20151316.</Citation>
        </Reference>
        <Reference>
          <Citation>Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med [Internet]. 2021; Jun 23 [cited 2021 Jun 30]; Available from: http://www.nature.com/articles/s41591-021-01433-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Rhea EM, Logsdon AF, Hansen KM, Williams LM, Reed MJ, Baumann KK, et al.  The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice. Nat Neurosci. 2021;24(3):368–378. doi: 10.1038/s41593-020-00771-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41593-020-00771-8</ArticleId>
            <ArticleId IdType="pmc">PMC8793077</ArticleId>
            <ArticleId IdType="pubmed">33328624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Littlejohn G, Guymer E. Neurogenic inflammation in fibromyalgia. Semin Immunopathol. 2018;40(3):291–300. doi: 10.1007/s00281-018-0672-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-018-0672-2</ArticleId>
            <ArticleId IdType="pubmed">29556959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>VanElzakker MB, Brumfield SA, Lara Mejia PS. Neuroinflammation and cytokines in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a critical review of research methods. Front Neurol. 2019;10(9):1033. doi: 10.3389/fneur.2018.01033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2018.01033</ArticleId>
            <ArticleId IdType="pmc">PMC6771300</ArticleId>
            <ArticleId IdType="pubmed">31608007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al.  Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis. 2021;5:ciab611.</Citation>
        </Reference>
        <Reference>
          <Citation>Coury F, Rossat A, Tebib A, Letroublon M-C, Gagnard A, Fantino B, et al.  Rheumatoid arthritis and fibromyalgia: a frequent unrelated association complicating disease management. J Rheumatol. 2009;36(1):58–62. doi: 10.3899/jrheum.080366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.080366</ArticleId>
            <ArticleId IdType="pubmed">19132794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aloush V, Ablin JN, Reitblat T, Caspi D, Elkayam O. Fibromyalgia in women with ankylosing spondylitis. Rheumatol Int. 2007;27(9):865–868. doi: 10.1007/s00296-007-0344-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-007-0344-3</ArticleId>
            <ArticleId IdType="pubmed">17476510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salaffi F, Giorgi V, Sirotti S, Bongiovanni S, Farah S, Bazzichi L, et al. The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. Clin Exp Rheumatol. 2021;39 Suppl 130(3):72–7.</Citation>
        </Reference>
        <Reference>
          <Citation>Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19 [internet]. Allerg Immunol. 2021 Jan [cited 2021 Aug 28]. Available from:. 10.1101/2021.01.27.21250559.</Citation>
        </Reference>
        <Reference>
          <Citation>Goebel A, Krock E, Gentry C, Israel MR, Jurczak A, Urbina CM, et al.  Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Investig. 2021;131(13):e144201. doi: 10.1172/JCI144201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI144201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A. Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int. 2014;34(9):1275–1280. doi: 10.1007/s00296-014-2972-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-014-2972-8</ArticleId>
            <ArticleId IdType="pubmed">24589726</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
